AyurDatta Launch — Summary

On October 13, 2025, AyurDatta was announced as a new full-service company focused on accelerating drug development by combining clinician-led scientific strategy with an AI-driven operational platform. The founders, Dr. Ashok Srivastava (clinical development and oncology leader) and Elias Tharakan (technology and operations executive), position the firm to help biopharma sponsors — especially in oncology, hematology, and rare diseases — translate scientific breakthroughs into submission-ready programs more quickly and reliably.

The announcement explains AyurDatta's integrated service model: clinical development strategy, medical monitoring and pharmacovigilance, global regulatory affairs, and technology-enabled execution. The company emphasizes a single accountable team that blends deep medical insight with compliant AI and process automation to reduce friction in complex trials and improve timelines.

The founders are quoted describing a shared mission: to eliminate gaps between clinical science and operational delivery, and to deliver high-quality, submission-ready data through a combination of physician-led review and automated, auditable systems. The release also highlights the founders' prior experience and the company's headquarters in Princeton, NJ.

Attribution & full text: this summary is an original paraphrase of the public press release published on openPR. Read the original release at: openPR — Industry Veterans Dr. Ashok Srivastava and Elias Tharakan Launch AyurDatta